학술논문
Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants
Document Type
article
Author
Linda van Oosten; Jort J. Altenburg; Cyrielle Fougeroux; Corinne Geertsema; Fred van den End; Wendy A. C. Evers; Adrie H. Westphal; Simon Lindhoud; Willy van den Berg; Daan C. Swarts; Laurens Deurhof; Andreas Suhrbier; Thuy T. Le; Shessy Torres Morales; Sebenzile K. Myeni; Marjolein Kikkert; Adam F. Sander; Willem Adriaan de Jongh; Robert Dagil; Morten A. Nielsen; Ali Salanti; Max Søgaard; Timo M. P. Keijzer; Dolf Weijers; Michel H. M. Eppink; René H. Wijffels; Monique M. van Oers; Dirk E. Martens; Gorben P. Pijlman
Source
mBio, Vol 12, Iss 5 (2021)
Subject
Language
English
ISSN
2150-7511
Abstract
Vaccines pave the way out of the SARS-CoV-2 pandemic. We have developed a virus-like particle (VLP)-based vaccine using the baculovirus-insect cell expression system, a robust production platform known for its scalability, low cost, and safety. Baculoviruses were constructed encoding SARS-CoV-2 spike proteins: full-length S, stabilized secreted S, or the S1 domain. This two-component nanoparticle vaccine can now be further developed to help alleviate the burden of COVID-19.